Abstract: Objective: The effect of bovine casein glycomacropeptide (CGMP) on MUC2 expression in mice with ulcerative colitis (UC) was investigated to explore the therapeutic efficacy of CGMP for UC. Methods: Mice were randomly divided into four groups including normal control group, model control group, CGMP group and sulfasalazine (SASP) group. UC model establishment was carried out by enema administration of oxazolone. The mice in the model control and normal control groups were given regular feed, and the mice in the CGMP group and SASP group were administered with CGMP at the dose of 50 mg/(kg ·d) and SASP at the dose of 40 mg/(kg ·d) after for 5 consecutive days, respectively. The changes in body weights and disease activity index (DAI) were recorded every day. The colon was separated to conduct HE staining and MUC2 immunohistochemical staining and record visible lesion score. Results: CGMP could effectively alleviate ulcerative colitis and reduce visible lesions in the mouse colon. HE staining revealed integrated epithelial cells in the colon of CGMP-treated mice. Meanwhile, IHC staining confirmed that CGMP could promote the secretion of MUC2 in the mouse colon. Conclusion: CGMP can alleviate colon inflammation by promoting the secretion of MUC2 in the mouse colon to enhance the barrier protection of intestinal mucosa.

Key words: casein glycomacropeptide(CGMP), ulcerative colitis, MUC2